within Pharmacolibrary.Drugs.ATC.B;

model B01AF03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.62,
    Cl             = 0.00037,
    adminDuration  = 600,
    adminMass      = 60 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.107,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0098,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.056299999999999996,
    k12             = 35.8,
    k21             = 35.8
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B01AF03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Edoxaban is an oral, direct factor Xa inhibitor anticoagulant used for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for the treatment and prevention of deep vein thrombosis and pulmonary embolism. It is approved in several countries including the US, EU, and Japan.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after administration of 60 mg oral dose in healthy adult subjects (male and female).</p><h4>References</h4><ol><li><p>Hindley, B, et al., &amp; Penson, PE (2023). Pharmacokinetics and pharmacodynamics of direct oral anticoagulants. <i>Expert opinion on drug metabolism &amp; toxicology</i> 19(12) 911–923. DOI:<a href=\"https://doi.org/10.1080/17425255.2023.2287472\">10.1080/17425255.2023.2287472</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37991392/\">https://pubmed.ncbi.nlm.nih.gov/37991392</a></p></li><li><p>Elenjickal, EJ, et al., &amp; Mavrakanas, TA (2024). Anticoagulation in Patients with Chronic Kidney Disease. <i>American journal of nephrology</i> 55(2) 146–164. DOI:<a href=\"https://doi.org/10.1159/000535546\">10.1159/000535546</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38035566/\">https://pubmed.ncbi.nlm.nih.gov/38035566</a></p></li><li><p>Parasrampuria, DA, &amp; Truitt, KE (2016). Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. <i>Clinical pharmacokinetics</i> 55(6) 641–655. DOI:<a href=\"https://doi.org/10.1007/s40262-015-0342-7\">10.1007/s40262-015-0342-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26620048/\">https://pubmed.ncbi.nlm.nih.gov/26620048</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B01AF03;
